These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22139760)

  • 1. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2012 Aug; 32(8):3091-5. PubMed ID: 22843878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological role and prognostic significance of NAC1 in ovarian cancer.
    Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
    Li J; Zhong M; Song LL; Su GD
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression.
    Peiró G; Diebold J; Löhrs U
    Am J Clin Pathol; 2002 Dec; 118(6):922-9. PubMed ID: 12472286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.
    Sun G; Zhou J; Yin A; Ding Y; Zhong M
    Int J Oncol; 2008 May; 32(5):1065-71. PubMed ID: 18425333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
    Zhong M; Li J; Ding YQ; Song LL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.
    Okamoto A; Sehouli J; Yanaihara N; Hirata Y; Braicu I; Kim BG; Takakura S; Saito M; Yanagida S; Takenaka M; Yamaguchi N; Morikawa A; Tanabe H; Yamada K; Yoshihara K; Enomoto T; Itamochi H; Kigawa J; Matsumura N; Konishi I; Aida S; Aoki Y; Ishii N; Ochiai K; Akiyama T; Urashima M
    PLoS One; 2015; 10(2):e0116977. PubMed ID: 25658832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The candidate oncogene ZNF217 is frequently amplified in colon cancer.
    Rooney PH; Boonsong A; McFadyen MC; McLeod HL; Cassidy J; Curran S; Murray GI
    J Pathol; 2004 Nov; 204(3):282-8. PubMed ID: 15476264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.
    Huang G; Krig S; Kowbel D; Xu H; Hyun B; Volik S; Feuerstein B; Mills GB; Stokoe D; Yaswen P; Collins C
    Hum Mol Genet; 2005 Nov; 14(21):3219-25. PubMed ID: 16203743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
    Katagiri H; Nakayama K; Razia S; Nakamura K; Sato E; Ishibashi T; Ishikawa M; Iida K; Ishikawa N; Otsuki Y; Nakayama S; Kyo S
    Int J Oncol; 2015 Dec; 47(6):2037-44. PubMed ID: 26458502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of ZNF217 in human ovarian cystadenocarcinoma and its clinical significance].
    Sun GQ; Zhong M; Ding YQ; Su GD; Song TR; Yin AL
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):685-8. PubMed ID: 19403395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Morikawa A; Hayashi T; Kobayashi M; Kato Y; Shirahige K; Itoh T; Urashima M; Okamoto A; Akiyama T
    Oncol Rep; 2018 Jul; 40(1):309-318. PubMed ID: 29749539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.